Sun Pharma has reaffirmed its long-term strategy of driving growth through specialty medicines, innovation, and differentiated products, according to its latest investor presentation released on the stock exchanges.

The company also reaffirmed its commitment to research-led growth, noting that its cumulative investment in R&D has reached approximately Rs. 33,500 crore, reflecting its focus on novel therapies, complex generics and global clinical development.

The innovative medicines contributed to 22% of its total sales in FY26. 

Sun Pharma said it remains focused on increasing the share of innovative and complex products while directing future investments towards differentiated therapies and technologies.

For FY26, the company reported gross sales of Rs. 58,220 crore, an EBITDA of Rs. 17,731 crore, translating into an EBITDA margin of 30.3%.

The company invested 6.1% of sales in research and development, underscoring its continued emphasis on innovation. As of May 2026, the company had a market capitalization of approximately US$45 billion.

Sun Pharma said it remains India's largest pharmaceutical company with an 8.4% market share, retaining the No. 1 prescription ranking across 11 physician specialties. 

In the United States, Sun Pharma continues to strengthen its specialty and generics businesses. The company highlighted the FY26 launches of Leqselvi and Unloxcyt, alongside the acquisition of Checkpoint Therapeutics, a move that expands its oncology portfolio through immunotherapy and targeted cancer therapies.

The company also outlined its strategy to deepen its presence in emerging markets, where it operates in over 80 countries with key focus markets including Romania, Russia, South Africa, Brazil, and Mexico. Its branded generics business is supported by more than 3,300 sales representatives and local manufacturing facilities across several geographies, positioning the company to benefit from rising pharmaceutical demand in developing economies.

In developed international markets outside the US, Sun Pharma is expanding its portfolio of innovative medicines and differentiated hospital products across Western Europe, Canada, Japan, Australia, New Zealand and Israel. The presentation also highlights continued expansion through previous acquisitions and launches, including Ilumya, Cequa and Winlevi, strengthening its specialty dermatology and immunology franchise.

On the manufacturing front, the company said it operates 40 manufacturing facilities approved by major global regulators, including the US FDA, and employs more than 47,000 people worldwide.